Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions (INSPIRE)

28 octobre 2026 mis à jour par: Michael Incze

Feasibility of a Remote Collaborative Care-Facilitated Contingency Management-Exercise Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary Conditions

The purpose of this study is to evaluate the feasibility and preliminary effectiveness of increasing control over stimulant use and physical health through incentivized rehabilitation (INSPIRE). INSPIRE is a 12-week remotely-delivered collaborative care intervention for rural patients with Methamphetamine-Associated Heart Failure (Me-HF) or Methamphetamine-Associated Pulmonary Arterial Hypertension (Me-PAH) featuring smartphone-based contingency management incentivizing participation in remote synchronous rehabilitation.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

45

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Active methamphetamine use determined by positive urine drug testing within the past 3 months and/or self-reported current use
  • Current diagnosis of chronic heart failure or pulmonary hypertension documented in the electronic health record
  • Possession of a smartphone
  • Able to participate in virtual exercise rehabilitation

Exclusion Criteria:

  • Currently incarcerated
  • Unable to interact with smartphone app and/or virtual health coaching sessions in English
  • Unstable arrhythmia, defined as any known arrhythmia that is associated with hemodynamic effects like syncope, hypotension, or decompensated heart failure
  • Decompensated chronic heart failure or pulmonary hypertension
  • NYHA class IV symptoms
  • Myocardial infarction within the past 3 months, percutaneous coronary intervention within the past 2 weeks, coronary artery bypass graft within the past 3 months, or implantable cardiac defibrillator/cardiac resynchronization therapy/pacemaker implantation within the last 6 weeks
  • Unstable angina, uncontrolled hypertension, acute myocarditis/pericarditis, intracardiac thrombus
  • Severe symptomatic aortic stenosis

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: INSPIRE

Participants randomized to INSPIRE will receive usual medical care plus a 12-week program featuring collaborative care and app-based contingency management incentivizing participation in remotely-delivered synchronous exercise rehabilitation sessions

Standard medical care plus a 12-week program featuring collaborative care and app-based contingency management incentivizing participation in remotely-delivered synchronous exercise rehabilitation sessions

Comparateur actif: Usual Care

Participants randomized to Usual Care will receive standard of care services routinely available at the University of Utah, including specialty cardiology, pulmonology and addiction care and in-person cardiac and pulmonary rehabilitation services

Standard care services routinely available at the University of Utah Health, including specialty cardiology, pulmonology and addiction care and in-person cardiac and pulmonary rehabilitation services

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in metabolic equivalents (METs)
Délai: Baseline, 1, 3, and 6 months

Change in METs before and after the intervention measured via Duke Activity Status Indicator (DASI)

Baseline, 1, 3, and 6 months
Change in self-reported substance use
Délai: Baseline, 1, 3, and 6 months

Change in self-reported substance use amount and frequency via Timeline Follow Back (TLFB)

Baseline, 1, 3, and 6 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Quality of Life - Short Form 20
Délai: Baseline, 1, 3, and 6 months

Measure of participants' quality of life using the Short Form 20 (SF-20) questionnaire. The score range of this survey is 0-100, with higher scores indicating better overall quality of life.

Baseline, 1, 3, and 6 months
Quality of Life - Kansas City Cardiomyopathy Questionnaire-12
Délai: Baseline, 1, 3, and 6 months

Measure of participant's quality of life using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). The score range of this survey is 0-100, with higher scores indicating better functioning and less limitation from heart failure symptoms.

Baseline, 1, 3, and 6 months
Self-Efficacy Related to Avoiding Substance Use with the Drug Avoidance Self-Efficacy Scale (DASES). The score range of this survey is 0-96, with higher scores indicating better self-efficacy to avoid substance use.
Délai: Baseline, 1, 3, and 6 months

Measure of self-efficacy to avoid substance use with the Drug Avoidance Self-Efficacy Scale (DASES).

Baseline, 1, 3, and 6 months
Recovery Capital using the Brief Assessment of Recovery Capital (BARC-10) questionnaire
Délai: Baseline, 1, 3, and 6 months

Measure of the internal and external resources (recovery capital) that help initiate and sustain recovery from substance use disorder, using the Brief Assessment of Recovery Capital (BARC-10) questionnaire. The score range of this survey is 10-60, with higher scores indicating a greater amount of recovery capital.

Baseline, 1, 3, and 6 months
Contingency Management App Engagement
Délai: 3 months and 6 months

Number of weekly App Log-Ins, Contingency Management Draws and Earnings

3 months and 6 months
Hospital Readmissions in the Past 30 Days
Délai: Baseline, 1, 3, and 6 months

Self-Reported Hospital admissions in the past 30 days using Timeline Follow Back

Baseline, 1, 3, and 6 months
Emergency Department Visits in the Past 30 days
Délai: Baseline, 1, 3, and 6 months

Self-Reported number of ED visits in the past 30 days using Timeline Follow Back

Baseline, 1, 3, and 6 months
Urgent Care Visits in the Past 30 Days
Délai: Baseline, 1, 3, and 6 months

Self-Reported number of urgent care visits in the past 30 days using Timeline Follow Back

Baseline, 1, 3, and 6 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
INSPIRE Acceptability assessed via 4-item Intervention Acceptability Measure (IAM)
Délai: immediately after the intervention (12 weeks from randomization)

Measure of INSPIRE acceptability through the IAM survey collected one time from all patient participants one time at the end of the intervention

immediately after the intervention (12 weeks from randomization)
INSPIRE Appropriateness assessed via 4-item Appropriateness of Intervention Measure (AIM)
Délai: immediately after the intervention (12 weeks from randomization)

Measure of INSPIRE appropriateness through Appropriateness of Intervention Measure (AIM) collected one time from all patient participants one time at the end of the intervention

immediately after the intervention (12 weeks from randomization)
Reach of the Intervention Over the Entire Study Period
Délai: Measured starting from the first randomization and ending after the final participant is randomized (up to 100 weeks after first randomization)

Number of different counties and states represented by enrolled participants measured from the first randomization to the final randomization.

Measured starting from the first randomization and ending after the final participant is randomized (up to 100 weeks after first randomization)
Sustainment of intervention
Délai: Measured between 12 weeks (end of intervention) and 24 weeks after randomization

Number of intervention participants who continue to log into the contingency management/peer support app in the three months after the intervention ends as assessed through app utilization data

Measured between 12 weeks (end of intervention) and 24 weeks after randomization
Feasibility
Délai: Measured starting from the first randomization and ending after the final participant has completed the intervention, discontinued the study, or was lost to follow-up (up to 112 weeks after first randomization)

Average number of enrollments per month and percentage of enrolled participants who complete the intervention

Measured starting from the first randomization and ending after the final participant has completed the intervention, discontinued the study, or was lost to follow-up (up to 112 weeks after first randomization)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Michael A Incze, MD, University of Utah

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

13 octobre 2026

Achèvement primaire (Estimé)

31 octobre 2028

Achèvement de l'étude (Estimé)

31 octobre 2028

Dates d'inscription aux études

Première soumission

12 octobre 2026

Première soumission répondant aux critères de contrôle qualité

28 octobre 2026

Première publication (Réel)

4 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Individual de-identified responses to the following surveys will be preserved and shared: 1) SF-20, 2) Kansas City Cardiomyopathy Questionnaire-12, 3) DASI, 4) TLFB data, 5) Drug Avoidance Self-Efficacy Scale, 6) BARC-10, 7) Appropriateness of Intervention Measure, 8) Intervention Acceptability Measure, and 9) App engagement and CM earnings data, 10) Self-reported data on substance use and acute care utilization, 11) demographic and substance use history enrollment surveys. De-identified biometric data and qualitative interview transcripts will also be preserved and shared.

All data will be stored within a secure computing environment. All participant identifiers (e.g., names and addresses) will be removed and maintained in a secure file for future contact purposes. Participant identifiers will not be shared.

Délai de partage IPD

Data will be available within 12 months of study conclusion

Critères d'accès au partage IPD

Data will be archived in The Hive. The Hive is a publicly-accessible repository for research data generated by UHealth researchers, students, and staff. It is maintained by the Marriott Library IT and Digital Collections. The Hive has policies and procedures in place that will provide data access to qualified researchers, fully consistent with NIH data-sharing policies and applicable laws and regulations. Deidentified data within The Hive will be shared with other investigators who propose specific aims/hypotheses in order to identify the data elements required and who receive agreement from the appropriate project leaders.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner